Moderna (MRNA) said Friday its trial for a trivalent vaccine against norovirus is currently on hold by the US Food and Drug Administration after a single adverse event report of a close of Guillain-Barre syndrome.
Investigation of the adverse event is currently underway, according to the company.
Moderna said it expects the clinical hold will not impact the efficacy readout timeline for the northern hemisphere trial as enrollment has already been completed.
Shares were up nearly 4% in recent trading.
Price: 33.07, Change: +1.15, Percent Change: +3.60
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。